United Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,480,600.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $896,950.62. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total value of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00.

United Therapeutics Stock Performance

Shares of UTHR traded up $7.67 on Tuesday, reaching $353.31. The stock had a trading volume of 508,279 shares, compared to its average volume of 319,429. The firm has a market capitalization of $15.78 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. The company has a 50-day simple moving average of $362.37 and a 200-day simple moving average of $358.13. United Therapeutics Co. has a 12-month low of $210.64 and a 12-month high of $417.82.

Analyst Upgrades and Downgrades

Several research firms have weighed in on UTHR. TD Cowen raised their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $382.08.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $25,000. Brooklyn Investment Group purchased a new position in shares of United Therapeutics in the 3rd quarter valued at approximately $33,000. Millstone Evans Group LLC purchased a new position in United Therapeutics during the fourth quarter valued at $67,000. Capital Performance Advisors LLP purchased a new position in United Therapeutics during the third quarter valued at $82,000. Finally, MassMutual Private Wealth & Trust FSB raised its stake in United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.